Neuraxis, Inc. (NRXS) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Neuraxis, Inc. is a growth-stage medical device company specializing in neuromodulation therapies. Its primary revenue-generating product is the IB-STIM device, indicated for functional abdominal pain in patients aged 8 and older. The company also markets the RED device for evaluating rectal expulsion function. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $1,607,883 | $895,655 |
| Gross Profit | $1,389,517 | $756,180 |
| Gross Margin | 86.4% | 84.4% |
| Operating Loss | $(1,740,679) | $(2,295,098) |
| Net Loss | $(1,761,432) | $(2,278,684) |
| Cash and Equivalents (End of Period) | $7,078,659 | $2,005,370 |
| Working Capital | $5,328,867 | $2,941,091 |
| Notes Payable (Current) | $100,735 | $148,293 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 79.5% year-over-year, driven by the effective date of the IB-STIM Category I CPT code on January 1, 2026, and broader insurance coverage adoption.
- Expense Reduction: General and Administrative (G&A) expenses decreased 9.3% to $2.2 million, primarily due to the absence of a one-time $619,097 litigation settlement charge recorded in Q1 2025.
- Improved Loss Profile: Operating loss improved by 24.2% and Net Loss improved by 22.7%, reflecting higher gross profit and reduced one-time legal costs.
- Liquidity Expansion: Cash balances increased by approximately $2.1 million, fueled by $2.99 million in proceeds from an At-The-Market (ATM) offering and $507,000 from warrant exercises.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Future operations depend on securing insurance coverage and raising additional capital.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including ineffective approval processes, inadequate contract management, and misapplication of U.S. GAAP. Remediation is ongoing but not yet complete.
- Litigation: A $750,000 settlement regarding a 2019 lawsuit is being paid in installments; $528,799 remains accrued as of March 31, 2026. A separate patent dispute with Dr. Arturo Taca remains unresolved.
- Subsequent Events: In April and May 2026, the company issued additional shares via ATM offerings and warrant exercises, raising further capital. The Board also approved a plan to cancel stock options and grant immediate-vesting RSUs, which may result in approximately $4.25 million in incremental compensation costs.
Investor Verification Checklist
- Verify the sustainability of the 79.5% revenue growth and the extent of insurance carrier adoption for the IB-STIM device beyond Q1 2026.
- Assess the timeline and cost implications of remediation for the identified material weaknesses in internal controls.
- Monitor the cash burn rate relative to the $7.1 million cash balance to evaluate the runway before additional financing is required.
- Review the impact of the proposed stock option to RSU exchange on future dilution and compensation expenses.
- Confirm the status of the Dr. Arturo Taca patent dispute and potential financial exposure.